ABSTRACT
AIMS: Advanced glycation endproducts (AGEs) have been associated with the development and progression of chronic heart failure (CHF). Advanced glycation endproducts-crosslink breakers might be of benefit in HF, but only small-scale and uncontrolled data are available. Our aim was to conduct a prospective, randomized, double-blind, placebo-controlled study to examine the effects of the AGE-breaker alagebrium on exercise capacity and cardiac function in patients with HF. METHODS AND RESULTS: One hundred and two patients with HF (78% male, aged 62 ± 11 years), and a left ventricular ejection fraction (LVEF) ≤0.45, were randomized to either 200 mg alagebrium twice daily or placebo. After 36 weeks, the primary efficacy end-point peak VO(2) had changed by (mean ± SEM) -2.1 ± 0.5 mL/min/kg in alagebrium vs. -0.5 ± 0.7 mL/min/kg in placebo-treated patients (P= 0.06). No significant changes were observed in a number of secondary end-points, including diastolic function (mean E': P= 0.32; E/E': P= 0.81), systolic function (LVEF: P= 0.43), AGE accumulation (skin-autofluorescence: P= 0.42), N-terminal pro brain natriuretic peptide, P= 0.20); New York Heart Association functional class (P= 0.73), patient global assessment (P= 0.32), physicians global assessment (P= 0.76), and the Minnesota Living with Heart Failure Questionnaire score (P= 0.38). Overall alagebrium was reasonably well tolerated. CONCLUSION: In the present proof-of-concept study, the AGE-breaker alagebrium did not improve exercise tolerance in patients with HF and systolic dysfunction, and no changes were observed in a number of secondary endpoints. The present data therefore do not support earlier data which suggested a beneficial effect of alagebrium in systolic HF. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00516646 (http://clinicaltrials.gov).
Subject(s)
Cardiovascular Agents/therapeutic use , Exercise Tolerance/drug effects , Glycation End Products, Advanced/antagonists & inhibitors , Heart Failure/drug therapy , Thiazoles/therapeutic use , Aged , Chronic Disease , Diagnostic Techniques, Cardiovascular , Double-Blind Method , Female , Heart Failure/diagnosis , Heart Failure/physiopathology , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
AIMS: To investigate the relationship between advanced glycation end-products (AGEs) and diastolic function and the response to blood pressure treatment in patients with hypertension and diastolic dysfunction. METHODS AND RESULTS: Data were analysed from 97 patients (aged 65 +/- 10 years, 36% male) who were randomly assigned to 6 months open-label treatment with either eprosartan on top of other anti-hypertensive drugs (n = 47) or other anti-hypertensive drugs alone (n = 50). Tissue AGE accumulation was measured using a validated skin-autofluorescence (skin-AF) reader (n = 26). Plasma N(epsilon)-(carboxymethyl)lysine (CML), N(epsilon)-(carboxyethyl)lysine (CEL), and pentosidine were measured by LC-MS/MS and HPLC. Diastolic function was assessed using echocardiography. Blood pressure was reduced from 157/91 to 145/84 mmHg (P < 0.001) in the eprosartan group and from 158/91 to 141/83 mmHg (P < 0.001) in the control group. No effect of eprosartan was found on AGE levels. In patients with baseline skin-AF < median, E/A ratio (P = 0.04) and the mean peak early-diastolic filling velocity (E') improved (P = 0.001). In contrast, in patients with skin-AF levels > median, E/A ratio (P = 0.84) and mean E' (P = 0.32) remained unchanged. CONCLUSION: Although eprosartan did not decrease levels of AGEs, patients with lower skin-AF at baseline showed a larger improvement in diastolic function in response to either anti-hypertensive treatment compared with patients with higher skin-AF.
Subject(s)
Angiotensin II Type 1 Receptor Blockers/therapeutic use , Antihypertensive Agents/therapeutic use , Glycation End Products, Advanced , Hypertension/drug therapy , Acrylates/therapeutic use , Aged , Diastole/drug effects , Female , Humans , Imidazoles/therapeutic use , Linear Models , Lysine/analogs & derivatives , Male , Middle Aged , Multivariate Analysis , Netherlands , Skin , Statistics as Topic , Statistics, Nonparametric , Stroke Volume , Thiophenes/therapeutic use , Ventricular Function, LeftABSTRACT
AIMS: Previous small open label studies have shown that the advanced glycation end-product (AGE) breaker alagebrium may improve cardiac function in patients with chronic heart failure (HF). We report the design, methods and baseline characteristics of a double-blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium (BENEFICIAL) in patients with HF and a left ventricular ejection fraction (LVEF) Subject(s)
Glycation End Products, Advanced/antagonists & inhibitors
, Heart Failure/drug therapy
, Thiazoles/therapeutic use
, Diastole
, Double-Blind Method
, Echocardiography, Stress
, Exercise Test
, Exercise Tolerance
, Female
, Health Status Indicators
, Heart Failure/diagnostic imaging
, Humans
, Male
, Middle Aged
, Oxygen Consumption
, Research Design
, Stroke Volume
, Surveys and Questionnaires
, Systole
, Ventricular Function, Left